Wednesday, 25 December 2024 04:41

Stem cell therapy to correct heart failure in children could 'transform lives'

Rate this item
(0 votes)

Renowned visionary English physician William Harvey wrote in 1651 about how our blood contains all the secrets of life.

"And so I conclude that blood lives and is nourished of itself and in no way depends on any other part of the body as being prior to it or more excellent," he wrote. "So that from this we may perceive the causes not only of life in general … but also of longer or shorter life, of sleeping and waking, of skill, of strength and so forth."

Kevin Watt, team leader of the Heart Regeneration and Disease Laboratory at the Murdoch Children’s Research Institute (MCRI) in Melbourne, Australia, understands this concept deeply. 

He lives it every day, as he and his fellow researchers study and reprogram the potential of the blood to treat disease, specifically heart failure in children

Building on the work of Dr. Shinya Yamanaka of Japan, who discovered that specialized cells could be reprogrammed back to immature stem cells, Watt and his collaborators have taken this work several steps further. 

They have used small molecules to turn these new stem cells from the blood into heart cells.

Small heart organoids are developed in the lab — which can then be injected into the failing hearts of children. 

Relying on the philanthropic support of the Murdoch Institute, the work is progressing rapidly and has been shown to be effective already in mice, pigs and sheep.

Clinical trials in humans will be starting soon, and as Dr. Watt told me in an interview from Australia, "Large sheets of heart tissue will be stitched into the failing heart." 

Congenital heart failure as well as side effects of chemotherapy in children will be targets for this miracle therapy. Millions of children around the world suffer daily from these conditions. 

Watt said that certain chemotherapy (anthracyclines) have a higher risk of heart failure – up to 15% of the time – and this treatment may be useful to protect the heart.

Watt said, "Heart failure remains an urgent, unmet clinical challenge across the world. While we have made significant advances over several decades in managing the disease, we lack targeted therapies to treat these devastating conditions."

He added, "More than 500,000 children around the world live with advanced heart failure that requires transplantation. The vision of our research is to develop new therapies that can transform the lives of children with heart failure."

To achieve this, he said, "we use a technology called induced pluripotent stem cells, where we can convert blood or skin cells of patients with heart failure into stem cells that we then turn into heart cells … or even make engineered heart tissues that can be stitched onto the patient’s heart to help it pump." 

The cells that are targeted in the blood are known as peripheral blood mononuclear cells (PBMCs). 

They are "pushed back in time to an earlier time before they became differentiated into heart or kidney cells," he said. 

Then they can be pushed forward to become healthy heart cells or mutations — or other abnormalities can be corrected.

While the team at the Murdoch Children’s Research Institute is making heart cells from stem cells in the blood for clinical use, it's also using these stem cells to figure out new drugs to treat heart failure directly.  

Said Watt, "Using stem cells from patients with heart failure caused by chemo, we are actively developing new drugs and cell-based treatments that we believe will transform the lives of patients with these conditions … Our research group has pioneered methods to turn these stem cells into miniature heart tissues that can be used to model disease-in-a-dish, to identify new drug targets for the development of new therapies."

These treatments are personalized and highly expensive, but they're also highly effective.

Correcting heart failure in young children is only a few years away from becoming a reality. 

It's a Christmas miracle that relies on the kind of philanthropic support that MCRI is famous for arranging.

"Philanthropic support plays a critical role in accelerating the development of these new, transformative treatments," said Watt, "and this support will be essential as we work toward bringing stem cell-based precision therapies for heart failure to every child who needs it." 

 

Fox News

February 06, 2025

IBM exits Nigeria, others; transfers operations to another company

International Business Machines (IBM) Corporation, an American multinational technology company, has announced plans to exit…
February 01, 2025

Tinubu targeting opposition, not corruption — Atiku

Former Vice President and Peoples Democratic Party (PDP) presidential candidate, Atiku Abubakar, has criticized the…
February 02, 2025

Moving away from BMI, experts propose a new definition for obesity

A group of global experts is proposing a new way to define and diagnose obesity,…
February 01, 2025

Humans to compete against humanoid robots at half-marathon

China’s capital city of Beijing is all set to host an interesting half-marathon that will…
February 03, 2025

Gunmen kill 10 in attack on Ebonyi community – Police

The Ebonyi State Police Command has confirmed the killing of 10 people in an attack…
February 06, 2025

Here’s the latest as Israel-Hamas war enters Day 489

Arab American, Muslim leaders decry Trump comments on Gaza U.S. Arab American and Muslim leaders,…
February 03, 2025

OpenAI introduces new AI tool to assist in research tasks

Leading generative artificial intelligence company OpenAI unveiled a new AI tool on Sunday named "Deep…
January 08, 2025

NFF appoints new Super Eagles head coach

The Nigeria Football Federation (NFF) has appointed Éric Sékou Chelle as the new Head Coach…

NEWSSCROLL TEAM: 'Sina Kawonise: Publisher/Editor-in-Chief; Prof Wale Are Olaitan: Editorial Consultant; Femi Kawonise: Head, Production & Administration; Afolabi Ajibola: IT Manager;
Contact Us: [email protected] Tel/WhatsApp: +234 811 395 4049

Copyright © 2015 - 2025 NewsScroll. All rights reserved.